FIG 1.

(A) Estimated numbers and proportions of excess deaths among childhood and adolescent cancer cases diagnosed at 0-19 years of age in the United States between 1975 and 2016, according to years from diagnosis by diagnosis, sex, and race (≤ 5.0 years after diagnosis [majority of excess deaths would be related to progressive disease, infection, or acute toxicity]; 5.0-9.9 years [excess deaths would reflect a mixture of recurrence or progressive disease plus deaths associated with treatment exposures]; ≥ 10.0 years post diagnosis [majority of excess deaths would be related to treatment exposures, with few from recurrence or progressive disease]); (B) estimated numbers of excess deaths among all childhood and adolescent cancer diagnosed at 0-19 years of age in the United States between 1975 and 2016, according to calendar year of death and years from diagnosis; (C) estimated numbers of excess deaths; and (D) absolute excess deaths per 1,000 patients or survivors at risk among childhood and adolescent patients with ALL, CNS malignancy, and HL, diagnosed at 0-19 years of age in the United States between 1975 and 2016, according to calendar year of death and years from diagnosis. ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ES, Ewing sarcoma; GCT, germ cell tumor; HL, Hodgkin lymphoma; Liver, liver carcinomas; NBL, neuroblastoma; NHL, non-Hodgkin lymphoma; OS, osteosarcoma; RB, retinoblastoma; Renal, renal carcinomas; Rhabdo, rhabdomyosarcoma; STS, soft-tissue sarcoma.